Precision rTMS for Smoking Cessation: Targeting Neural Circuits

The MagVenture International Sales Meeting (ISM) 2026 concluded with a comprehensive look at the future of Transcranial Magnetic Stimulation (TMS). The final day focused on how recent technological breakthroughs and regulatory clearances will shape clinical practice in 2027 and beyond. Key Day 3 Highlights & Future Roadmap:. The T-Series Generation: Partners explored the full potential of the new T65 coil , the first in a series of lighter, high-performance cooled coils. This "dual-purpose" design is now the benchmark for clinical efficiency, handling both motor threshold (MT) determination and treatment., Precision Psychiatry: Demonstrations highlighted the integration of the MagVenture TMS Atlas™ and newly acquired neuronavigation assets, emphasizing MRI-guided precision as a standard for future clinical workflows., Expanding Indications: Following the milestone FDA clearance for Adolescent Depression (ages 15-21) , the roadmap emphasized reaching younger populations and addressing "anxious depression" with specialized single-coil protocols., Chronic Pain Frontiers: Strategic discussions reviewed the growth of MagVenture Pain Therapy , focusing on non-invasive peripheral nerve stimulation as a high-demand alternative to pharmacological pain management., Global Collaboration: The meeting closed with a commitment to providing localized training through the MagVenture Educate platform, ensuring distributor excellence across more than 50 countries.